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BACKGROUND
•	Ipilimumab has been shown to improve
overall survival in patients with advanced
melanoma.
•	Ipilimumab is a human monoclonal
antibody that blocks CTLA-4, a protein
receptor on T cells that results in
therapeutic upregulation of cytotoxic T
cells that have anti-tumor effect.
•	However, ipilimumab can cause immunemediated effects that range from mild
to life-threatening conditions colitis,
fulminant hepatitis, nephritis, hypophysitis,
and toxic epidermal necrolysis.

CASE PRESENTATION

DISCUSSION AND FOLLOW-UP

•	A 43 year-old Caucasian female with recent diagnosis of malignant melanoma status post
excision and adjuvant chemotherapy with high dose ipilimumab presented to the hospital with
three day history of progressively worsening cramping abdominal pain associated with diarrhea.
•	Initial Abdominal CT (Image 1) showed pancolitis and C-reactive protein (CRP) was elevated at
70mg/l.
•	After a negative infectious work, her symptoms were attributed to autoimmune colitis from her
immunotherapy with ipilimumab.
•	She was treated with steroids and had rapid resolution of her symptoms and the patient was
discharged on tapering doses of steroids
•	Two months later, patient presented with recurrent symptoms.
•	Repeat CT Abdomen (Image 2) showed new inflammatory changes in the stomach and jejunum.
•	Further evaluation with Esophagogastroduodenoscopy (EGD) showed diffuse gastritis and
duodenitis (Image 3).
•	Histopathology showed inflammatory gastric mucosa.
•	Flexible sigmoidoscopy showed diffuse circumferential granular colitis.
•	Treatment with infliximab and high dose steroids resulted in quick resolution of symptoms.

Discussion:
•	Ipilimumab causes dysregulation of gastrointestinal (GI)
mucosal immunity commonly manifesting as immune related
adverse events ( irAEs )such as colitis but can also involve the
esophagus, stomach, duodenum and the ileum.
•	There have been many described cases of autoimmune colitis
secondary to ipilimumab therapy but this case highlights
the diffuse involvement of the upper and lower GI system
caused by a single dose of ipilimumab requiring multiple
hospitalizations and its refractoriness to tapering doses of
steroids and infliximab.
Follow-up:
•	The patient is currently maintained on chronic oral steroids
and budesonide.
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